Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMYNASDAQ:NXLNASDAQ:PSTVNASDAQ:QTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.80$1.10$0.69▼$1.80$21.79M-2.62251,564 shs382,354 shsNXLNexalin Technology$1.29+8.4%$1.51$0.53▼$4.49$22.16M41.24 million shs113,876 shsPSTVPlus Therapeutics$0.33+2.0%$0.61$0.24▼$2.58$5.53M0.885.28 million shs2.71 million shsQTIQT Imaging$0.79+9.0%$0.72$0.35▼$0.86$21.30M-0.2159,999 shs27,257 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys0.00%-21.57%-29.82%-46.67%-27.93%NXLNexalin Technology-4.03%0.00%-5.56%-50.00%+73.72%PSTVPlus Therapeutics-9.55%+11.38%-36.19%-79.68%-86.87%QTIQT Imaging+0.17%-6.64%-12.85%+68.82%+1.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFEMYFemasys3.5823 of 5 stars3.55.00.00.02.22.51.3NXLNexalin Technology2.7372 of 5 stars3.55.00.00.00.63.30.0PSTVPlus Therapeutics1.4351 of 5 stars3.32.00.00.01.60.00.6QTIQT ImagingN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 3.00Buy$8.67983.33% UpsideNXLNexalin Technology 3.00Buy$5.00287.60% UpsidePSTVPlus Therapeutics 2.50Moderate Buy$11.673,484.23% UpsideQTIQT Imaging 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PSTV, FEMY, QTI, and NXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $20.505/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/5/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/5/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/21/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $20.003/28/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/28/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/28/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $5.503/24/2025NXLNexalin TechnologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$5.003/19/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$1.70M12.82N/AN/A$0.85 per share0.94NXLNexalin Technology$131.07K169.07N/AN/A$0.43 per share3.00PSTVPlus Therapeutics$4.91M1.13N/AN/A($0.30) per share-1.09QTIQT Imaging$4.00M5.33N/AN/A($1.91) per share-0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$14.25M-$0.91N/AN/AN/A-1,435.77%-141.49%-82.30%8/14/2025 (Estimated)NXLNexalin Technology-$4.65M-$0.83N/A∞N/A-3,407.98%-187.59%-167.21%N/APSTVPlus Therapeutics-$13.32M-$2.94N/AN/AN/A-225.07%N/A-154.56%8/13/2025 (Estimated)QTIQT Imaging-$4.03MN/A0.00∞N/AN/AN/A-65.94%8/6/2025 (Estimated)Latest PSTV, FEMY, QTI, and NXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2025PSTVPlus Therapeutics-$0.17-$0.56-$0.39-$1.19$1.11 million$1.06 million5/13/2025Q1 2025NXLNexalin Technology-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 million5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 million3/27/2025Q4 2024FEMYFemasys-$0.25-$0.23+$0.02-$0.23$1.66 million$0.58 million3/27/2025Q4 2024PSTVPlus Therapeutics-$0.51-$0.67-$0.16-$0.67$1.19 million$1.80 million3/14/2025Q4 2024NXLNexalin TechnologyN/A-$0.28N/A-$0.28N/A$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/AQTIQT ImagingN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.863.943.26NXLNexalin TechnologyN/A16.4215.89PSTVPlus TherapeuticsN/A0.440.44QTIQT ImagingN/A1.060.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%NXLNexalin Technology0.65%PSTVPlus Therapeutics3.28%QTIQT Imaging24.19%Insider OwnershipCompanyInsider OwnershipFEMYFemasys11.54%NXLNexalin Technology24.00%PSTVPlus Therapeutics3.76%QTIQT Imaging75.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3027.24 million20.08 millionNot OptionableNXLNexalin Technology317.18 million10.11 millionNot OptionablePSTVPlus Therapeutics2017.00 million5.57 millionNot OptionableQTIQT ImagingN/A27.13 million6.68 millionN/APSTV, FEMY, QTI, and NXL HeadlinesRecent News About These CompaniesQT Imaging (NASDAQ:QTI) Stock Price Down 2.9% - Here's WhyMay 28, 2025 | americanbankingnews.comLadenburg Thalmann Initiates Coverage of QT Imaging Holdings (QTIH) with Buy RecommendationMay 20, 2025 | msn.comQT Imaging Holdings Delivers Its Breast Imaging Scanner to Innovative Radiology in Des Moines, IowaMay 15, 2025 | finance.yahoo.comQT Imaging Holdings Announces $200,000 PIPE InvestmentMay 14, 2025 | joplinglobe.comQT Imaging Announces First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comQT Imaging Approves Executive Stock Options PlanApril 23, 2025 | tipranks.comQT Imaging Holdings Announces $500,000 Insiders PIPE InvestmentApril 10, 2025 | businesswire.comQT Imaging Holdings Announces $500,000 Insiders PIPE InvestmentApril 10, 2025 | businesswire.comQT Imaging Holdings to Participate in the 2025 SBI Breast Imaging SymposiumApril 8, 2025 | businesswire.comQT Imaging Announces Fourth Quarter and Full Year 2024 Financial Results and Provides 2025/26 OutlookApril 2, 2025 | seekingalpha.comQT Imaging Holdings Announces Shipment of Six QT Breast Acoustic CT Scanners in the First Quarter of 2025April 1, 2025 | businesswire.comQT Imaging Holdings Receives $10.1 Million in New Funding to Support Working Capital and Retire DebtFebruary 27, 2025 | businesswire.comQTI Stock Earnings: QT Imaging Holdings Reported Results for Q2 2024February 14, 2025 | investorplace.comQT Imaging Holdings Inc. secures sublease agreementJanuary 24, 2025 | msn.comQT Imaging Holdings Introduces Machine Learning-Enabled Image Interpolation Algorithm to Substantially Reduce Scan TimeJanuary 15, 2025 | joplinglobe.comQT Imaging Holdings Announces Clearing of All Its Short-Term Liabilities and Forecasts Solid Revenue GrowthJanuary 13, 2025 | finance.yahoo.comQT Imaging Holdings Announces New Commercial Shipment in Partnership with Couri CenterDecember 12, 2024 | finance.yahoo.comQT Imaging Holdings to Attend Radiological Society of North America 2024 Annual MeetingNovember 21, 2024 | finance.yahoo.comQT Imaging Holdings, Inc. (NASDAQ:QTI) Director Acquires $248,287.56 in StockNovember 15, 2024 | insidertrades.comQTI Stock Earnings: QT Imaging Holdings Reported Results for Q2 2024November 15, 2024 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSTV, FEMY, QTI, and NXL Company DescriptionsFemasys NASDAQ:FEMY$0.80 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$0.83 +0.03 (+3.75%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Nexalin Technology NASDAQ:NXL$1.29 +0.10 (+8.40%) Closing price 04:00 PM EasternExtended Trading$1.30 +0.00 (+0.39%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.Plus Therapeutics NASDAQ:PSTV$0.33 +0.01 (+2.04%) Closing price 04:00 PM EasternExtended Trading$0.33 +0.00 (+0.15%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.QT Imaging NASDAQ:QTI$0.78 +0.07 (+9.03%) As of 06/5/2025QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems for detection, diagnosis, monitoring, and treatment of diseases. The company offers QT Ultrasound Breast Scanner, an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient's breast. QT Imaging Holdings, Inc. was founded in 2011 and is based in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
